Oregon is currently home to 1222 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
NCT06067438
Recruiting
This phase II trial studies how well amiodarone works in the prevention of atrial fibrillation (AF) after a minimally invasive esophagectomy (MIE) in patients with esophageal cancer. Atrial fibrillation (AF) is an irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atria. AF is the most common complication after MIE for esophageal cancer. There has never been a study of AF after MIE that has used unbiased assignment of patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Atrial Fibrillation, Esophageal Carcinoma
Register for Updates
Testing Continuous Versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma
NCT05976763
Recruiting
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
01/13/2025
Locations: Providence Newberg Medical Center, Newberg, Oregon
Conditions: Mantle Cell Lymphoma
Register for Updates
Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
NCT05700994
Recruiting
The main goal of this study is to tests the effect of incentivizing achievement of self-identified, personal harm reduction goals (Contingency management or CM) compared with standard of care (peer harm reduction service with incentives for peer visits) to increase the reach and effectiveness of methamphetamine (MA) harm reduction services.
Gender:
ALL
Ages:
Between 18 years and 105 years
Trial Updated:
01/13/2025
Locations: Comagine Health, Portland, Oregon
Conditions: Methamphetamine Abuse
Register for Updates
Testing the Addition of Immunotherapy Before Surgery for Patients with Sarcomatoid Mesothelioma
NCT05647265
Recruiting
This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Saint Charles Health System, Bend, Oregon
Conditions: Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma
Register for Updates
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults with B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
NCT05303792
Recruiting
This phase II trial compares the combination of inotuzumab ozogamicin and chemotherapy to the usual chemotherapy in treating patients with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a drug, called CalichDMH. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers CalichDMH to kill them.... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
01/13/2025
Locations: Saint Alphonsus Cancer Care Center-Ontario, Ontario, Oregon
Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Register for Updates
Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients
NCT04217551
Recruiting
A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Adventist Health, Portland, Oregon
Conditions: Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
Register for Updates
Genetic Testing in Guiding Treatment for Patients with Brain Metastases
NCT03994796
Recruiting
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Saint Alphonsus Cancer Care Center-Baker City, Baker City, Oregon
Conditions: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Register for Updates
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
NCT03471260
Recruiting
This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome
Register for Updates
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas
NCT02523014
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Saint Alphonsus Cancer Care Center-Baker City, Baker City, Oregon
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Register for Updates
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
NCT06081894
Recruiting
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/11/2025
Locations: Providence St. Vincent Medical Center, Portland, Oregon
Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Register for Updates
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273
Recruiting
This is a randomized, open-label study in adult patients who have completed standard first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogen... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Oncology Associates of Oregon, Eugene, Oregon
Conditions: Large B-cell Lymphoma
Register for Updates
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
NCT06045689
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Oncology Associates of Oregon, P.C., Eugene, Oregon
Conditions: Myelodysplastic Syndromes
Register for Updates